Citius Pharmaceuticals, Inc. (CTXR) Form 8-K Material Events
Citius Pharmaceuticals, Inc. (CTXR) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: CTXR
CIK: 1506251
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 09/30
State: NV
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Wolf & Company, P.C.
Auditor SinceSince 9/30/2017 12:00:00 AM
Lead Engagement PartnerDerek Thomas
Audit LocationBoston, Massachusetts, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-08-21 | 2026-08-17 | CURRENT REPORT | 0001213900-26-092604 | View SEC Doc Filr Page |
| 10-Q | 2026-08-14 | 2026-06-30 | QUARTERLY REPORT | 0001213900-26-090185 | View SEC Doc Filr Page |
| 8-K | 2026-08-14 | 2026-08-14 | CURRENT REPORT | 0001213900-26-090181 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001649553-26-000102 | View SEC Doc Filr Page |
| UPLOAD | 2026-08-10 | — | UPLOAD Filing | 0000000000-26-007819 | View SEC Doc Filr Page |
| 8-K | 2026-08-05 | 2026-08-05 | CURRENT REPORT | 0001213900-26-085432 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-06-04 | — | SCHEDULE 13D/A Filing | 0001213900-26-065310 | View SEC Doc Filr Page |
| EFFECT | 2026-06-02 | — | EFFECT Filing | 9999999995-26-001857 | View SEC Doc Filr Page |
| 8-K | 2026-06-01 | 2026-06-01 | CURRENT REPORT | 0001213900-26-063531 | View SEC Doc Filr Page |
| CORRESP | 2026-05-29 | — | CORRESP Filing | 0001213900-26-062830 | View SEC Doc Filr Page |
| S-3 | 2026-05-22 | — | REGISTRATION STATEMENT | 0001213900-26-060644 | View SEC Doc Filr Page |
| 8-K | 2026-05-15 | 2026-05-15 | CURRENT REPORT | 0001213900-26-057876 | View SEC Doc Filr Page |
| 10-Q | 2026-05-15 | 2026-03-31 | QUARTERLY REPORT | 0001213900-26-057842 | View SEC Doc Filr Page |
| 8-K | 2026-05-08 | 2026-05-04 | CURRENT REPORT | 0001213900-26-053916 | View SEC Doc Filr Page |
| 8-K | 2026-04-29 | 2026-04-23 | CURRENT REPORT | 0001213900-26-049338 | View SEC Doc Filr Page |
| 8-K | 2026-04-24 | 2026-04-23 | CURRENT REPORT | 0001213900-26-047599 | View SEC Doc Filr Page |
| 424B5 | 2026-04-24 | — | PROSPECTUS SUPPLEMENT | 0001213900-26-047296 | View SEC Doc Filr Page |
| 8-K | 2026-04-06 | 2026-04-06 | CURRENT REPORT | 0001213900-26-040474 | View SEC Doc Filr Page |
| 8-K | 2026-03-31 | 2026-03-31 | CURRENT REPORT | 0001213900-26-037524 | View SEC Doc Filr Page |
| 8-K | 2026-03-10 | 2026-03-10 | CURRENT REPORT | 0001213900-26-025459 | View SEC Doc Filr Page |
| 8-K | 2026-03-04 | 2026-03-04 | CURRENT REPORT | 0001213900-26-023439 | View SEC Doc Filr Page |
| ARS | 2026-02-24 | 2025-09-30 | FORM ARS | 0001213900-26-019569 | View SEC Doc Filr Page |
| DEFA14A | 2026-02-24 | — | DEFINITIVE ADDITIONAL MATERIALS | 0001213900-26-019568 | View SEC Doc Filr Page |
| DEF 14A | 2026-02-24 | 2026-04-06 | DEFINITIVE PROXY STATEMENT | 0001213900-26-019566 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-02-17 | — | SCHEDULE 13G/A Filing | 0001649553-26-000024 | View SEC Doc Filr Page |